Latest News

The listing below shows our latest News Items and is updated regularly.  If you wish to post a news item please select the 'Post News' button on the right.  The displayed news feed starts on 1st August 2016.  Older items can be found here.



Oxford Immunotec Schedules Fourth Quarter and Full Year 2016 Earnings Release and Conference Call for February 28, 2017

OXFORD, United Kingdom and MARLBOROUGH, Mass., February 14, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced that it plans to release fourth quarter and full year 2016 financial results after the close of the market on Tuesday, February 28, 2017. Dr. Peter Wrighton-Smith, Chief Executive Officer, and Rick Altieri, Chief Financial Officer, will host a conference call to review the Company's results at 5:00 p.m. Eastern Time the same day. The call will be concurrently webcast.

Read the rest of entry »

NIHR Brain Injury Healthcare Technology Co-operative – Seedcorn Funding Competition 2016/2017 – FUNDING CALL ROUND 2 NOW OPEN

The NIHR Brain Injury Healthcare Technology Co-operative is pleased to announce the second round of its second national competition. The seed funding call (up to £10,000) is for the early development of novel technology-based solutions applicable to the brain injury pathway, from prevention of injury all the way through to technologies for independent living.  Applications are invited from academic institutions, NHS Trusts, third sector organisations and SME’s.

Read the rest of entry »

Oxford BioTherapeutics Strengthens Board of Directors with Appointment of Two Biotech Veterans

Oxford, UK & San Jose, USA - Oxford BioTherapeutics (“OBT”), an international biotechnology company developing clinical stage antibody therapeutics for cancer, today announced a significant strengthening of its oncology focused Board of Directors with the appointment of Bernd Seizinger M.D., Ph.D. as Chairman and Jean-Pierre Bizzari, M.D. as a non-executive director, joining Glenn Begley, Shawn Tomasello, Tom Bradley and Christian Rohlff.

Read the rest of entry »

Contractor appointed for £13 million landmark Oxford scheme

Oxford, UK - The Oxford Science Park has awarded a £13 million design and build contract for Plot 12, a new state of the art office building, capable of housing laboratories, and with roof terrace, comprising 61,500 sq ft (5,713 sq m), to Barnwood Construction Ltd.

Read the rest of entry »

Cutting Edge Tools for Neuroscience Research

Abingdon, UK - AMSBIO has published a new 25-page Neuroscience catalogue that details its extensive range of specific tools and reagents to enable researchers stay at the forefront of their field.

Read the rest of entry »

Summit Therapeutics to Participate in February Investor Conferences

Oxford, UK - Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, announces that company management will participate in three upcoming investor conferences taking place in New York City in February.

Read the rest of entry »

Chronos CEO awarded 2016 Best European CEO in the Drug Discovery Industry

Oxford, UK - Chronos Therapeutics Ltd (Chronos), the private biotech company focused on ageing diseases, brain and nervous system disorders, is honoured to announce that Dr Huw Jones, CEO of Chronos, has been awarded Best CEO in the European Drug Discovery Industry by online and print magazine European CEO.

Read the rest of entry »

Arecor Awarded £1.05M from Innovate UK to Support the Advancement of its Diabetes Glucagon Product Towards Clinical Trials

Cambridge, UK - Arecor's Prototype liquid glucagon product shows stability and commercial viability - Partnership with Innovate UK to accelerate pre-clinical asset towards proof-of-concept & first-in-human trials.

Read the rest of entry »

Oxford Immunotec to Present at the Leerink Partners 6th Annual Global Healthcare Conference

Oxford, UK & Marlborough, USA - Oxford Immunotec Global PLC, a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced Richard Altieri, Chief Financial Officer, will present at the Leerink Partners 6th Annual Global Healthcare Conference on Thursday, February 16, 2017, at 10:00 a.m. EST at the Lotte New York Palace in New York City.

Read the rest of entry »

Summit Outline Phase 3 Programme for Novel CDI Antibiotic Ridinilazole

Oxford, UK – Summit Therapeutics plc, the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection (‘CDI’), today outlines its Phase 3 programme for its novel antibiotic, ridinilazole, following recent regulatory meetings with the US Food and Drug Administration (‘FDA’) and European Medicines Agency (‘EMA’).

Read the rest of entry »

Search Posts

News Policy

OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.

OBN Noticeboard

This is an impromptu noticeboard to let people know about events, other things that are happening, perhaps lab equipment for sale etc.  Just drop an email to us, team@obn.org.uk, and we will post.

Don't forget about the 'wandering kitchens' near No. 99 on Milton Park on Thursday lunchtime!